 risk leukemia relapse high-dose cyclosporine allogeneic marrow transplantation acute leukemia patients acute myeloid leukemia ANLL acute lymphoblastic leukemia ALL years mg/kg day group mg/kg day group cyclosporine CyA day day bone marrow transplant BMT patients CyA patients cyclophosphamide CY mg/kg total body irradiation TBI unfractionated BM HLA-identical sibling groups comparable diagnosis disease status French-American-British FAB classification WBC count diagnosis cytogenetic abnormalities extramedullary disease BMT donor/recipient age sex number cells number days intravenous IV CyA Median follow-up patients group days group Patients group serum levels CyA ng/mL bilirubin levels mg/dL creatinine levels mg/dL proportion cells peripheral blood PB day First day /L neutrophils comparable groups days Cox model actuarial risk acute graft-v-host disease GVHD II+ stratification age years group patients actuarial risk chronic GVHD comparable Actuarial transplant-related mortality TRM days group major cause death GVHD group multiorgan toxicity group actuarial risk relapse years overall group group patients first remission patients non-first complete remission CR Actuarial disease-free survival DFS group patients first remissions advanced disease ABSTRACT TRUNCATED AT WORDS